Neuvivo develops NP001, a novel immunotherapy targeting the immune system to treat Amyotrophic Lateral Sclerosis (ALS). The company focuses on addressing neuroinflammation and restoring balance in the neuro-immune system implicated in motor neuron destruction. Their work aims to halt disease progression and potentially promote healing across the neuromuscular system in ALS patients.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Amyotrophic lateral sclerosis (ALS) is characterized by progressive loss of motor neurons, leading to muscle weakness and eventual paralysis. Current treatments for ALS have limitations, leaving a significant unmet need for therapies that can effectively slow disease progression and improve patient outcomes. Systemic inflammation and abnormal inflammatory macrophage/microglia activity within affected spinal cord and brain regions are key factors in the progressive loss of motor function in ALS.
Solution
Neuvivo is developing NP001, an investigational small molecule therapeutic designed to address chronic inflammation associated with ALS. NP001 aims to modulate macrophage activity, converting inflammatory M1 macrophages to neuroprotective M2 macrophages. By targeting inflammatory macrophages, NP001 seeks to mitigate neuroinflammation, slow motor neuron degeneration, and improve the quality of life for ALS patients. Clinical trials of NP001 have demonstrated its potential to slow the progression of ALS and protect motor neurons, with no drug-related serious adverse events reported to date.
Target Audience
The primary target audience includes individuals living with ALS, as well as clinicians and researchers focused on developing effective and safe treatments for ALS and other neurodegenerative diseases.
Features
- NP001: A proprietary small molecule investigational therapeutic.
- Macrophage Modulation: Transforms inflammatory M1 macrophages to the non-inflammatory, wound-healing M2 state.
- Neuroprotection: Aims to stop damage to motor neurons.
- Clinical Validation: Demonstrated ability to slow disease progression in clinical trials.
- Orphan Drug and Fast Track Designation: Granted by the FDA.
- Potential Application: May have a role in addressing a range of CNS diseases, such as Parkinson’s Disease and Alzheimer’s Disease.
- Targets inflammation at the neuromuscular junction.